RNA sequencing of human pancreatic islets has provided important insights into the islet transcriptome but little information on the specific cells. In this issue, Segerstolpe et al. (2016) and Xin et al. (2016b) report on the transcriptome of single pancreatic cells from non-diabetic and type 2 diabetic donors.
While sequencing of whole pancreatic islets has provided useful information on the differences in gene expression profiles between islets from non-diabetic and type 2 diabetic (T2D) donors and their genetic regulation, i.e., expression quantitative trait loci (eQTLs) (Taneera et al., 2012; Nica et al., 2013; Fadista et al., 2014; van de Bunt et al., 2015) , only limited information is available on which specific cell types contribute to these differences (Blodgett et al.2015; Li et al., 2016 Figure 1A ).
In this issue of Cell Metabolism, Segerstolpe et al. (2016) and Xin et al. (2016b) performed single-cell RNA sequencing in islets isolated from non-diabetic and T2D donors and sequenced 2,209 and 1,492 cells at depths of 0.75 and 0.95 million reads. Xin et al. (2016b) also compared their results with previous data generated in mice (Xin et al., 2016a) . The cell-specific transcript pattern showed a significant overlap between the studies for 491 genes in a cells and 517 in b cells ( Figure 1B Figure 1C ). They also observed heterogeneity of a and b cells, i.e., b cells clustered into five groups, all of which expressed INS, and clusters 1 and 5 specifically expressed RPB4, previously shown to be upregulated in obese and T2D individuals. The same authors also identified a unique gene expression signature in a sub-cluster of a cells with proliferating capacity and suggested that they may have the potential to be transformed into b cells.
An intriguing part of the studies pertained to the differences observed between non-diabetic and T2D islets. Segerstolpe et al. showed a decline in b cell numbers and decreased INS expression in T2D compared with non-diabetic donors. Interestingly, both studies reported differential expression of the FXYD2 gene in b cells from T2D and non-diabetic donors, though in opposite directions. FXYD2 is an Na,K-ATPase, and mice lacking fyxd2 show b cell hyperplasia. Segerstolpe et al. showed that FXYD2 was the most downregulated gene in b cells from T2D donors, whereas Xin et al. found it upregulated. Segerstolpe et al. interpreted this downregulation as a homeostatic attempt to increase b cell number in diabetes.
Previous studies applying whole-islet sequencing have identified differences in gene expression between T2D and nondiabetic donors. The new data presented in this issue allow these differences to be assigned to specific pancreatic cells. In the Segerstolpe paper, only one gene previously shown to differ between T2D and non-diabetic islets, WSF1, showed decreased expression in a cells from T2D islets. The question remains whether this finding will cast new information on the pathogenesis of the Wolfram syndrome due to loss-of-function mutations in the WSF1 gene.
Altogether, the results presented by Segerstolpe et al. and Xin et al. provide key insights into the human islet cell transcriptome at the single-cell level. Single-cell RNA sequencing remains a relatively new technique and will require further refinement in order to generate reproducible datasets. Technical artifacts are common, particularly with the Fluidigm technique, which yields droplet or hybrid cells expressing several genes normally not co-expressed. As previously shown (Dorrell et al., 2016) , the cell sorting most likely destroyed more b than a cells, resulting in an incongruous proportion of a and b cells. There was also a marked heterogeneity at the single-cell level between donors, which had not been captured with bulk sequencing. It is also important to note that when comparing islets from T2D and non-diabetic donors, a few established players among the differentially expressed genes or cell-specific genes were missing, e.g., SLC30A8, MTNR1B (strongest eQTL in human pancreatic islets), TCF7L2, and KCJN11. A variant in the transcription factor TCF7L2 gene has been reported as the strongest association with T2D, but transcription factors are usually expressed at very low levels, which may explain why it is missing from the Segerstolpe et al. and Xin et al. studies. For many of these genes, it is still an open question whether the genetic variants primarily influence b cells, a cells, or other cells, and single-cell sequencing might help resolve this issue.
These new techniques clearly represent a breakthrough in diabetes research and will hopefully help us answer questions regarding the role of specific pancreatic cells in the pathogenesis of type 2 diabetes, including how genetic variants influence gene expression in a single cell.
